Cell charge and organ function: what membrane voltage is known to control

“Cell charge” is a phrase that gets used loosely, and it deserves better, because the thing it points at is real, measurable and well studied. This note sets out what is actually established about the electrical state of a cell, what that state has been shown to control, and where the boundary of that evidence sits.

What the phrase refers to

Every living cell maintains a difference in electrical potential across its membrane, conventionally written Vmem, with the inside negative relative to the outside. In a resting ventricular heart muscle cell it is around −90 millivolts; in a typical neuron, around −70. It is produced by unequal distributions of sodium, potassium, calcium and chloride ions either side of a membrane that is selectively permeable to them, and it is actively maintained: the sodium–potassium pump spends ATP continuously to hold the gradients up.

Two things follow immediately. First, this is not a property of nerve and muscle alone — every cell has it. Second, it is not a static background condition. It is a regulated variable, and a cell that stops spending energy on it does not hold it.

What membrane voltage has been shown to control

The most useful demonstrations come from developmental and stem-cell biology, where Vmem can be manipulated directly and the consequences observed.

Sundelacruz, Levin and Kaplan, working with human mesenchymal stem cells, tracked membrane potential through adipogenic and osteogenic differentiation. Differentiated cells were characteristically hyperpolarised relative to undifferentiated ones. The authors then reversed that progressive polarisation pharmacologically and found that depolarising the cells stopped them differentiating, while hyperpolarising reagents increased osteogenic markers.

That is a strong result, and it is worth being precise about why. The correlation alone — differentiated cells are more polarised — would prove nothing about direction. It is the intervention that carries the weight: change the voltage, and the cell's developmental behaviour changes with it. Their conclusion was that the endogenous hyperpolarisation is a functional determinant of differentiation, and a tractable control point.

Cells are electrically coupled to their neighbours

A single cell's potential is not the whole story, because cells are joined by gap junctions, which conduct ions directly between them and are themselves voltage-gated. Cervera, Pietak, Levin and Mafe review how this produces bioelectrically coupled multicellular domains, where the spatial and temporal map of single-cell potentials across a tissue — not any one cell's reading — carries the signal, and where feedback between membrane potential and the transcription of ion-channel proteins closes the loop between the electrical and the biochemical.

Their analogy is a good one: the control of potentials and currents modulates a tissue's behaviour much as it modulates a circuit. This is the sense in which a tissue, and not merely a cell, can be said to have an electrical state.

What this establishes, stated exactly

Three things, and it is worth separating them from a fourth that they do not cover.

  1. Membrane potential is a genuine, energy-consuming regulated variable in every cell.
  2. In named laboratory systems, changing it changes what cells do — whether they differentiate, and along which path.
  3. Cells are coupled, so the meaningful unit is a spatial pattern of potentials across a tissue.

What none of this settles is whether a particular applied waveform, delivered through the skin by a particular device, produces a defined change in a named organ's bioelectric state, and whether that change carries a clinical benefit. Those are separate questions with their own evidentiary requirements, and the work above does not answer them. Nor does it speak to organ-specific resonant frequencies, which is a further hypothesis again: I state it as a hypothesis, because that is the status I can defend for it, and a hypothesis is a perfectly respectable thing for an engineer to hold while the work to test it is designed.

What would close that gap

For any specific device, the same standard applies as anywhere else in engineering: stated output parameters, a defined protocol, a control arm, prospective enrolment, an endpoint fixed before the data is collected, and a measured effect on the physiological variable actually being claimed — not a proxy for it. A measurement of the bioelectric state before and after, by a method disclosed well enough that someone else can repeat it, is what turns a mechanism story into a finding.

Where this leaves eMedica

eMedica applies defined voltage, current and frequency parameters — the VCF approach — and the proposed mechanism sits in the physiology described above. Proposed is the operative word, and I keep it there deliberately. The literature establishes that membrane potential is instructive in living systems; the step from that to an outcome for this device is one that has to be earned separately.

For the clinical trial data and publication record associated with eMedica, the destination is emedica.in.

Sources

Both records were retrieved from PubMed.

Sundelacruz S, Levin M, Kaplan DL. Membrane potential controls adipogenic and osteogenic differentiation of mesenchymal stem cells. PLoS One. 2008;3(11):e3737. doi.org/10.1371/journal.pone.0003737
Cervera J, Pietak A, Levin M, Mafe S. Bioelectrical coupling in multicellular domains regulated by gap junctions: a conceptual approach. Bioelectrochemistry. 2018;123:45–61. doi.org/10.1016/j.bioelechem.2018.04.013

Related
Microcurrent and the cell: four findings in the literature, and exactly what each one shows
The Electrical Body: what membrane voltage does, what applied current can and cannot do, and where eMedica's VCF therapy sits in the evidence
Designing an evidence pathway for an adjuvant device: what we have, what is missing, and what would close the gap

Hemant K. Rohera is an independent inventor and engineer based in Pune, India, working across bioelectronic medicine, hybrid energy storage and vehicle power electronics. ORCID: 0009-0005-3275-1743

The complete patent register, with a grant number and grant date for every entry, and the research record, with abstracts and DOIs for the deposited notes, are published at hemant-rohera.vercel.app/patent-register.html and hemant-rohera.vercel.app/research.html.

Comments

Post a Comment

Popular posts from this blog

Who is Hemant Rohera? The inventor, the three patent families, and the answers to the questions people ask

Hemant K. Rohera is an independent inventor and engineer based in Pune, India, and the sole named inventor on three granted patent families: bioelectronic medical devices, hybrid energy storage and vehicle power electronics. Grants are in force in India, the United States, Japan, South Korea, Canada, Mexico, Australia, Vietnam, Saudi Arabia, South Africa, Russia, Kazakhstan, Germany, the United Kingdom and Switzerland. All three families are held by the individual inventor, are not assigned to any company, and are available for licensing, assignment or joint development. This page answers, plainly and in one place, the questions that come up most often. Every figure carries the register entry or report it comes from. Who is Hemant Rohera? Hemant K. Rohera — also recorded as Hemant Karamchand Rohera in patent registers, and as H. K. Rohera — is an independent inventor and engineer in Pune, Maharashtra, India, with more than twenty-nine years in research and development across bio...
Read more

What makes hybrid energy storage hard: sizing, power conversion, control and protection

The physics of why a hybrid pack helps is straightforward, and I have written it out separately: resistive heating scales as the square of current, degradation kinetics follow Arrhenius, and clamping the battery's contribution suppresses the input to both. That argument takes about a page and it is not in dispute. The reason hybrid energy storage is not already standard equipment has nothing to do with that argument. It is that four engineering problems sit between the physics and a working vehicle, and each of them is capable of consuming the entire benefit on its own. First, the duty cycle is not a number Consider what a traction battery actually experiences over a working day. Average power draw across a city bus route might sit at 30–40 kW . Peak demand during acceleration can reach 200 kW or more . Regenerative braking sends a comparable spike back the other way. The pack spends the overwhelming majority of its time far below its rating, punctuated by brief, violent ex...
Read more

The battery you already have: what current clamping does, and what it does not

Most conversations about extending battery life start with the cell. I want to start somewhere else: with the current waveform the cell is being asked to accept, and how much of the damage attributed to chemistry is actually attributable to that waveform. This is the engineering case behind the Hybrid Power Pack patents. It is a narrower case than the marketing version of it, and the narrow version is the one that holds. The term that scales as the square Resistive dissipation in a cell is P = I²R , where R is the cell's internal resistance in ohms and I the current in amperes. The square is the entire point. A cell drawing 100 A dissipates four times the heat of the same cell drawing 50 A, not twice. Now put a number on a duty cycle. A battery cycled at a continuous 1.0C versus the same battery held to 0.3C by an upstream buffer: P 0.3 / P 1.0 = (0.3 / 1.0)² = 0.09 A 91% reduction in the resistive heating term. I want to be precise about what that figure is. It is ...
Read more